Red cell phospholipids in schizophrenia

Lautin, Andrew; Cordasco, Donna Mandio; Segarnick, David J.; Wood, L. D. H.; Mason, M.F.; Wolkin, Adam; Rotrosen, John

doi:10.1016/0024-3205(82)90074-1

Cited by 29 publications

(9 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Initial reports found a marked increase in PtdSer (up to 50%) and a decrease in PtdEtn and Phosphatidylcholine (PtdCho) [78,79] leading to the proposal that the ratio of Phosphatidylethanolamine (PtdEtn) to Phosphatidylserine (PtdSer) might even be a biochemical marker for schizophrenia. The most consistent finding throughout most studies [3−5] was a decrease in PtdEtn (9−47%), although two groups [80,81] failed to replicate these findings. Significantly lower amounts of PtdEtn and PtdCho were also found in post‐mortem brain tissue from patients with schizophrenia [58], even after accounting for potential confounds.…”

Section: Methodsmentioning

confidence: 99%

Implications of lipid biology for the pathogenesis of schizophrenia

Berger¹,

Wood

Pantelis

et al. 2002

Aust NZ J Psychiatry

View full text Add to dashboard Cite

Peripheral blood cell, brain necropsy and 31P-MRS analysis reveal a disturbed lipid biology, suggesting generalized membrane alterations in schizophrenia. 31P-MRS data suggest increased membrane turnover at illness onset and persisting membrane abnormalities in established schizophrenia. Cellular processes regulating membrane lipid metabolism are potential new targets for antipsychotic drugs and might explain the mechanism of action of treatments such as eicosapentaenoic acid.

show abstract

Section: Methodsmentioning

confidence: 99%

Implications of lipid biology for the pathogenesis of schizophrenia

Berger¹,

Wood

Pantelis

et al. 2002

Aust NZ J Psychiatry

View full text Add to dashboard Cite

show abstract

“…Reduced plasma and RBC levels of phosphatidylcholine (PC) and phosphatidylethanolamine (PE) have been reported (Cai et al, 2012;He et al, 2012;Kaddurah-Daouk et al, 2007;Ryazantseva et al, 2002). Lautin et al (Lautin et al, 1982) measured RBC phospholipid levels in medicated schizophrenia patients and healthy controls but found no significant differences in PC, PE, phosphatidylserine (PS) or sphingomyelin (SM) concentrations. McEvoy et al (McEvoy et al, 2013) also reported no significant differences between schizophrenia patients and controls in plasma levels of overall LPC, PC or PE lipid classes however there were significant reductions in the PCn3 and PEn3 lipids in both first episode and recurrent episode patients compared to controls.…”

Section: Phospholipids and Lipoproteinsmentioning

confidence: 99%

A systematic review of metabolite biomarkers of schizophrenia

Davison

O’Gorman

Brennan

et al. 2018

Schizophrenia Research

123

View full text Add to dashboard Cite

Current diagnosis of schizophrenia relies exclusively on the potentially subjective interpretation of clinical symptoms and social functioning as more objective biological measurement and medical diagnostic tests are not presently available. The use of metabolomics in the discovery of disease biomarkers has grown in recent years. Metabolomic methods could aid in the discovery of diagnostic biomarkers of schizophrenia. This systematic review focuses on biofluid metabolites associated with schizophrenia. A systematic search of Web of Science and Ovid Medline databases was conducted and 63 studies investigating metabolite biomarkers of schizophrenia were included. A review of these studies revealed several potential metabolite signatures of schizophrenia including reduced levels of essential polyunsaturated fatty acids (EPUFAs), vitamin E and creatinine; and elevated levels of lipid peroxidation metabolites and glutamate. Further research is needed to validate these biomarkers and would benefit from large cohort studies and more homogeneous and well-defined subject groups.

show abstract

“…Initial reports found a marked increase in phosphatidylserine (PtdSer) (up to 50%) and a decrease in phosphatidylethanolamine (PtdEtn) (9-47%) and phosphatidylcholine (Henn, 1980;Stevens, 1972) leading to the proposal that the ratio of PtdEtn to PtdSer might be a biochemical marker for schizophrenia (Keshavan et al, 1993;Ripova et al, 1997;Rotrosen & Wolkin, 1987), although two groups (Hitzemann, Hirschowitz, & Garver, 1984;Lautin et al, 1982) failed to replicate these findings. Significantly lower amounts of PtdEtn and PtdCho were found in post mortem brain tissue from patients with schizophrenia (Yao et al, 2000b), even after accounting for potential confounds.…”

Section: Altered Glycerophospholipid (Gpl) Membrane Composition In Scmentioning

confidence: 89%

Bioactive lipids in schizophrenia

Berger

Smesny

Amminger

2006

International Review of Psychiatry

View full text Add to dashboard Cite

SummaryBioactive lipids, in particular arachidonic acid (AA), are vital for monoaminergic neurotransmission, brain development and synaptic plasticity. Phospholipases A2 (PLA2) are key-enzymes in AA metabolism and are activated during monoaminergic neurotransmission. Reduced membrane AA levels, and an altered activity of PLA2 have been found in peripheral membranes of drug-naïve patients with schizophrenia with some conflicting results in more chronic patient populations. Furthermore, in vivo brain phosphorus-31 magnetic resonance spectroscopy suggests reduced lipid membrane precursors (phosphomonoesters) and increased membrane breakdown products (phosphodiesters) in drug-naïve or early treated firstepisode schizophrenia patients compared to age-matched controls or chronic populations and these changes were correlated with peripheral red blood cell membrane AA levels. We postulate that processes modulating membrane lipid metabolism are associated with psychotic illnesses and might partially explain the mechanism of action of antipsychotic agents, as well as experimental agents such as purified ethyl-eicosapentaenoic acid (E-EPA). Recent supplementation trials suggest that E-EPA is a modestly effective augmentation treatment resulting in reduced doses of antipsychotic medication in acutely ill patients with schizophrenia (but not in residual-type schizophrenia). This review investigates the role of bioactive lipids in schizophrenia and its treatment, as well as its potential use in prevention.

show abstract

Red cell phospholipids in schizophrenia

Cited by 29 publications

References 11 publications

Implications of lipid biology for the pathogenesis of schizophrenia

Implications of lipid biology for the pathogenesis of schizophrenia

A systematic review of metabolite biomarkers of schizophrenia

Bioactive lipids in schizophrenia

Contact Info

Product

Resources

About